The latest price target for bioAffinity Technologies (NASDAQ:BIAF) was reported by Maxim Group on July 23, 2024. The analyst firm set a price target for $6.00 expecting BIAF to rise to within 12 months (a possible 520.35% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for bioAffinity Technologies (NASDAQ:BIAF) was provided by Maxim Group, and bioAffinity Technologies initiated their buy rating.

There is no last upgrade for bioAffinity Technologies

There is no last downgrade for bioAffinity Technologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bioAffinity Technologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bioAffinity Technologies was filed on July 23, 2024 so you should expect the next rating to be made available sometime around July 23, 2025.

While ratings are subjective and will change, the latest bioAffinity Technologies (BIAF) rating was a initiated with a price target of $0.00 to $6.00. The current price bioAffinity Technologies (BIAF) is trading at is $0.97, which is within the analyst’s predicted range.